Table 5.

Multivariate logistic regression analysis (stepwise analysis) of predictors of PASI 75, 90, and 100 response after treatment with guselkumab.

Variable	OR (95% CI)	p-Value
PASI 75
20 weeks
Number of PBT (low to high)	2.85 (1.41–5.88)	0.004
PASI 90
12 weeks
Number of PBT (low to high)	1.96 (1.14–3.45)	0.017
20 weeks
Number of comorbidities (low to high)	2.94 (1.32–6.25)	0.008
28 weeks
Number of PBT (low to high)	2.17 (1.22–3.85)	0.008
36 weeks
Number of comorbidities (low to high)	5.26 (1.37–20.00)	0.015
44 weeks
Number of comorbidities (low to high)	4.76 (1.33–16.67)	0.016
PASI 100
20 weeks
Number of PBT (low to high)	2.86 (1.47–5.88)	0.002
28 weeks
Number of PBT (low to high)	2.22 (1.27–4.00)	0.006
36 weeks
Number of PBT (low to high)	2.04 (1.16–3.70)	0.013
44 weeks
Number of comorbidities (low to high)	3.33 (1.30–9.09)	0.012
52 weeks
Number of comorbidities (low to high)	6.67 (1.25–33.33)	0.026

CI, confidence interval; OR, odds ratio; PASI, Psoriasis Area Severity Index; PBT, previous biologic treatment.